Field Trip is developing the experimental drug FT-104 as a potential new treatment for some psychiatric conditions such as postpartum depression (PPD), treatment resistant depression and post-traumatic stress disorder (PTSD). FT-104 belongs to a class of drugs called psychedelics. FT-104 has not been tested in humans.
The purpose of this study is:
- to investigate the safety and tolerability of FT-104 in healthy volunteers (without depression, PTSD or other mental illness)
- to assess the amount of FT-104 in the body over time when it is administered once
In each group of 8, 6 participants will receive the active drug (FT-104), and 2 will receive the placebo. You will be told which group you are part of but will not be told if you will receive FT-104 or placebo.
If you are eligible and enrolled in the study, you will be paid a total of $1100 for the screening, follow-up visits and adequate compliance of all study requirements. If you are an alternate, and do not get dosed, you will receive a partial payment of $150.
CAHLN Ethics have reviewed this study in detail and have approved its conduct.
If you would like to learn more about this research study and whether you are suitable to participate, please click “NEXT” to continue onto the questionnaire.
One of our Clinical Trial Coordinators will be in touch after you have submitted the form to discuss your eligibility for this trial.
~
If you would like further information prior to completion of this form, please visit our website or call us on 7074 4404 for more information.
~